News
MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback